The purpose of this study is to investigate metastatic pancreatic cancer. This study focuses on patients with a high tumor mutation burden.
This study investigates the effectiveness of a combined treatment approach. It evaluates how well the investigational medication combination works in treating the condition.
- Who can participate: Adults aged 18 and older who have pancreatic cancer with a high tumor mutation burden may be eligible. Participants must have measurable disease, an ECOG status of 0-1, and no prior treatments with similar investigational therapies.
- Study details: Participants will receive an investigational medication combination. An inactive substance that looks like the investigational medicine but does not contain any medicine.